Blood amyloid and tau biomarkers as predictors of cerebrospinal fluid profiles.


Journal

Journal of neural transmission (Vienna, Austria : 1996)
ISSN: 1435-1463
Titre abrégé: J Neural Transm (Vienna)
Pays: Austria
ID NLM: 9702341

Informations de publication

Date de publication:
02 2022
Historique:
received: 30 12 2021
accepted: 05 02 2022
pubmed: 17 2 2022
medline: 17 3 2022
entrez: 16 2 2022
Statut: ppublish

Résumé

Blood biomarkers represent a major advance for improving the management, diagnosis, and monitoring of Alzheimer's disease (AD). However, their context of use in relation to routine cerebrospinal fluid (CSF) analysis for the quantification of amyloid peptides and tau proteins remains to be determined. We studied in two independent cohorts, the performance of blood biomarkers in detecting "nonpathological" (A-/T-/N-), amyloid (A+) or neurodegenerative (T+ /N+) CSF profiles. Plasma Aβ The use of blood biomarkers to identify patients who may benefit from secondary CSF testing represents an attractive stratification strategy in the clinical management of patients visiting memory clinics. This could reduce the need for lumbar puncture and foreshadow the use of blood testing on larger populations.

Identifiants

pubmed: 35169889
doi: 10.1007/s00702-022-02474-9
pii: 10.1007/s00702-022-02474-9
pmc: PMC8866346
doi:

Substances chimiques

Amyloid beta-Peptides 0
Biomarkers 0
MAPT protein, human 0
Peptide Fragments 0
tau Proteins 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

231-237

Informations de copyright

© 2022. The Author(s).

Références

Proteomics Clin Appl. 2008 Oct;2(10-11):1548-56
pubmed: 21136802
J Alzheimers Dis. 2020;75(3):937-947
pubmed: 32390628
Alzheimers Dement (N Y). 2019 Oct 14;5:597-609
pubmed: 31650016
Lancet Neurol. 2014 Jun;13(6):614-29
pubmed: 24849862
Nat Med. 2021 Jun;27(6):1034-1042
pubmed: 34031605
J Neurol Neurosurg Psychiatry. 2018 May;89(5):467-475
pubmed: 29321140
Alzheimers Res Ther. 2021 Dec 4;13(1):198
pubmed: 34863295
Clin Chim Acta. 2019 Aug;495:451-456
pubmed: 31051163
Alzheimers Res Ther. 2020 Oct 2;12(1):123
pubmed: 33008460
Nature. 2018 Feb 8;554(7691):249-254
pubmed: 29420472
Alzheimers Dement. 2014 Oct;10(5 Suppl):S390-S394.e2
pubmed: 24269268
Alzheimers Dement. 2018 Apr;14(4):535-562
pubmed: 29653606
JAMA Neurol. 2021 Nov 1;78(11):1375-1382
pubmed: 34542571
Alzheimers Res Ther. 2018 Jul 28;10(1):71
pubmed: 30055655
Alzheimers Dement. 2018 Sep;14(9):1159-1170
pubmed: 30049650
Front Aging Neurosci. 2018 May 28;10:138
pubmed: 29892221
J Alzheimers Dis. 2011;26(3):553-63
pubmed: 21709372
Alzheimers Dement. 2021 Aug;17(8):1353-1364
pubmed: 33580742
Alzheimers Res Ther. 2020 Mar 17;12(1):26
pubmed: 32183883
J Neurol Neurosurg Psychiatry. 2021 Nov;92(11):1206-1214
pubmed: 34103344
BMC Bioinformatics. 2006 Oct 10;7:442
pubmed: 17032455
Alzheimers Dement. 2011 May;7(3):263-9
pubmed: 21514250
Biometrics. 1988 Sep;44(3):837-45
pubmed: 3203132
J Neurol. 2012 Nov;259(11):2429-33
pubmed: 22576334
Neurology. 2016 Aug 2;87(5):539-47
pubmed: 27371494

Auteurs

Constance Delaby (C)

Laboratoire de Biochimie Protéomique Clinique (LBPC-PPC), Univ Montpellier, CHU Montpellier, INM INSERM, Hôpital St Eloi, IRMB 80 av A Fliche, 34295, Montpellier, France.
Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain.

Daniel Alcolea (D)

Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain.

Christophe Hirtz (C)

Laboratoire de Biochimie Protéomique Clinique (LBPC-PPC), Univ Montpellier, CHU Montpellier, INM INSERM, Hôpital St Eloi, IRMB 80 av A Fliche, 34295, Montpellier, France.

Jérôme Vialaret (J)

Laboratoire de Biochimie Protéomique Clinique (LBPC-PPC), Univ Montpellier, CHU Montpellier, INM INSERM, Hôpital St Eloi, IRMB 80 av A Fliche, 34295, Montpellier, France.

Jana Kindermans (J)

Laboratoire de Biochimie Protéomique Clinique (LBPC-PPC), Univ Montpellier, CHU Montpellier, INM INSERM, Hôpital St Eloi, IRMB 80 av A Fliche, 34295, Montpellier, France.

Lisa Morichon (L)

Laboratoire de Biochimie Protéomique Clinique (LBPC-PPC), Univ Montpellier, CHU Montpellier, INM INSERM, Hôpital St Eloi, IRMB 80 av A Fliche, 34295, Montpellier, France.

Juan Fortea (J)

Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain.

Olivia Belbin (O)

Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain.

Audrey Gabelle (A)

CMRR, Univ Montpellier, CHU Montpellier, INM INSERM, Montpellier, France.

Kaj Blennow (K)

Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Sweden.
Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden.

Henrik Zetterberg (H)

Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Sweden.
Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden.
Department of Neurodegenerative Disease, UCL Institute of Neurology, Queen Square, London, UK.
UK Dementia Research Institute at UCL, London, UK.
Hong Kong Center for Neurodegenerative Diseases, Hong Kong, China.

Alberto Lleó (A)

Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain.

Sylvain Lehmann (S)

Laboratoire de Biochimie Protéomique Clinique (LBPC-PPC), Univ Montpellier, CHU Montpellier, INM INSERM, Hôpital St Eloi, IRMB 80 av A Fliche, 34295, Montpellier, France. s-lehmann@chu-montpellier.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH